Litcius/Paper detail

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy, R Moroose, IA Mayer, Vandana G. Abramson, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, Trishna Goswami, William A. Wegener, Aditya Bardia

2020Annals of Oncology145 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMetastatic breast cancerHormone receptorOncologyBreast cancerInternal medicineHER2 negativeCancerHER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesCancer Treatment and Pharmacology
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial | Litcius